During the 20th Asia Pacific League of Associations for Rheumatology (APLAR) Congress, held September 6 to 9 in Kaohsiung, Taiwan, researchers presented on real-world experience with switching to biosimilars in treating rheumatic diseases.
During the 20th Asia Pacific League of Associations for Rheumatology (APLAR) Congress, held September 6 to 9 in Kaohsiung, Taiwan, researchers presented on real-world experience with switching to biosimilars in treating rheumatic diseases.
First, research from Frimley Park Hospital in Camberley, United Kingdom, reported on a switch from reference etanercept (Enbrel) to a biosimilar (Benepali).1 The biosimilar agent was first brought to the UK marketplace in June 2016, and provided an opportunity for the local National Health Service trust partake in cost savings via a gain-sharing agreement.
Read more about UK hospitals and biosimilar switching.
The hospital collected data from clinic records for 103 patients with rheumatoid arthritis who were receiving etanercept. In total, 95% of these patients were switched to the biosimilar by February 2017. Prior to switching to the biosimilar, patients had a mean disease activity score in a count of 28 joints (DAS28) of 2.69. After the switch, the patients’ mean DAS28 score was 2.83, a change that was clinically insignificant.
Similarly, researchers from Queen Alexandra Hospital, in Portsmouth, United Kingdom, reported on switches to biosimilars of infliximab and etanercept in retrospective, observational audit of a cohort of 80 patients with RA.2
For 3 years, patients who had received reference infliximab (Remicade) and reference etanercept were stratified according to disease activity and were switched to available biosimilars.
When disease activity was measured by DAS28, in patients receiving infliximab who had remission or low disease activity (LDA), 87.5% had no change in disease activity, while 12.5% had disease worsening. In those with moderate to severe disease activity, 33.3% had no change, while 66.7% showed improvement.
In patients receiving etanercept, among those with remission or LDA, 91.7% remained stable. Of those with moderate to severe disease, 57.1% had no change in disease activity, while 42.9% showed improvement.
When patients were assessed by Power Doppler Ultrasound Score, disease activity correlated with DAS28 score in most cases. Overall, no statistically significant differences emerged between treatment with the reference drugs or biosimilars, say the investigators, noting that improvements in disease activity after switching could be due to placebo effect.
References
1. Hoshen D. Real world experience of etanercept biosimilar switching. Presented at the Asia Pacific League of Associations for Rheumatology Congress, September 6-9, 2018; Kaohsiung, Taiwan. Abstract FR072. doi: 10.1111/1756-185X.13361.
2. Ringer A, Bellenie H, Parkes M, Harvey G, Young-min S, Wong E. Switching from originators to biosimilars using DAS28 and ultrasound to measure disease activity: experience from Portsmouth, UK. Presented at the Asia Pacific League of Associations for Rheumatology Congress, September 6-9, 2018; Kaohsiung, Taiwan. Abstract FR076. doi: 10.1111/1756-185X.13361.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.